Home' Australian Pharmacist : Australian Pharmacist May 2015 Contents Australian Pharmacist May 2015 I ©Pharmaceutical Society of Australia Ltd.
Novartis Oncology and
A treatment option for Australians
living with chronic lymphocytic
leukaemia (CLL) who have not received
prior therapy and are inappropriate
for fludarabine-based therapy is now
available with the listing of Arzerra
(ofatumumab) in combination with
chlorambucil on the Pharmaceutical
Benefits Scheme (PBS) from 1 April. In
March Novartis Oncology acquired GSK’s
oncology portfolio. This acquisition
included Arzerra, a monoclonal antibody
used in combination with chlorambucil
or bendamustine for treating patients
with CLL. The PBS listing comes off the
back of research that shows treatment
with ofatumumab and chlorambucil
demonstrated a statistically significant,
longer median progression-free survival
(PFS) of 22.4 months compared to
chlorambucil alone (13.1 months).
Arzerra should not be used in
patients who are hypersensitive to
ofatumumab or to any of the excipients.
Care should be taken in patients
with hepatitis B, those who require
immunisations or have a history of
heart disease. Infusion reactions,
tumour lysis syndrome, progressive
multifocal leukoencephalopathy, bowel
obstructions and skin reactions have
been reported in patients receiving
Arzerra. Side effects associated with
treatment with Arzerra include infusion
reactions, cytopenias (neutropenia,
anaemia, febrile neutropenia,
and infections (lower respiratory tract
infection, including pneumonia, upper
respiratory tract infection, sepsis,
including neutropenic sepsis and septic
shock, herpes virus infection, urinary
1. Arzerra Approved Product Information. (Oct 2014)
plantarum) and cholesterol
Enliva is a complementary medicine which
may assist in the maintenance of normal
cholesterol levels in healthy individuals
and may also reduce intestinal absorption
of cholesterol from dietary sources.
Enliva is intended for use by patients not
yet eligible for, or who do not require,
prescription medication, who are seeking
to maintain healthy cholesterol in
combination with diet and exercise.
The complementary medicine contains
three proprietary strains of Lactobacillus
plantarum (CECT 7527, 7528, 7529)
specially selected to overcome
physicochemical barriers found in the
digestive tract to enable them to reach
the small intestine.
Enliva works by increasing the breakdown
of bile salts in the small intestine, leading
to increased use of cholesterol by the
body to synthesise new salts, and also
reduces the absorption of cholesterol
from the diet.
Lactobacillus products are generally
considered safe and well-tolerated, with
reports of only mild gastrointestinal side-
effects such as bloating.
For more information call: 1800 225 311
BGP Products Pty Ltd, trading as Mylan EPD, ABN 29
601 608 771. 299 Lane Cove Road, Macquarie Park
NSW 2113. Ph: 1800 225 311. ENLIVA is a registered
trademark. AU-ENL-2015-16 Date Prepared: 9th March
1. Fuentes M, et al. Br J Nutr 2013;109:1866-72
2. Enliva ARTG entry Available at www.ebs.tga.gov.au (Accessed
9 Mar 2015)
Brintellix® (vortioxetine) is the first
antidepressant to be approved
in Australia in almost five years,
and is indicated for the treatment
and prevention of relapse of major
depressive disorder in adults.
Affecting approximately 1 million
Australians each year, depression has
a significant effect on the health and
wellbeing of individuals, and places
strain on the economy through reduced
productivity.3-5 Research has shown that
job strain-attributable depression costs
the Australian economy A$730 million
Recognising depression in
the workplace and providing necessary
treatment and support is essential.
With multimodal activity, Brintellix is
efficacious in treating the symptoms
of depression (as assessed by MADRS
*) across a range of patient
Brintellix is available via private
*HAM-D24= 24-item Hamilton Depression Scale.
MADRS=Montgomery-Asberg Depression Rating
1. Australian Register of Therapeutic Goods (ARTG) 2015. At:
goods. Accessed Mar 2015.
2. Brintellix® (vortioxetine) Approved Product Information.
3. Estimating the economic benefits of eliminating job strain
as a risk factor for depression. VicHealth 2010. Accessed
4. The Facts. Beyond Blue Ltd 2015. Accessed Mar 2015.
5. What is depression? National Institute of Mental Health. At:
shtml. Accessed March 2015.
Links Archive Australian Pharmacist April 2015 Australian Pharmacist June 2015 Navigation Previous Page Next Page